MedPath

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Registration Number
NCT03539744
Lead Sponsor
AbbVie
Brief Summary

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
265
Inclusion Criteria
  • Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.
  • Measurable disease at screening as defined per protocol.
  • Has received at least 2 prior lines of therapy as described in the protocol.
  • Has had documented disease progression on or within 60 days after completion of the last therapy.
  • Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide, as defined per protocol.
  • Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).
  • Has t(11;14)-positive status determined by an analytically validated fluorescent in situ hybridization (FISH) assay per centralized laboratory testing.
  • An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.
Exclusion Criteria
  • History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.
  • History of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years (exceptions described in the protocol).
  • Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
  • Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.
  • Known central nervous system involvement of MM.
  • Concurrent conditions as listed in the protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm 1 VenDexDexamethasoneVenetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
Arm 2 PomDexDexamethasonePomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
Arm 1 VenDexVenetoclaxVenetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
Arm 2 PomDexPomalidomidePomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)Up to approximately 43 months from first randomization

PFS is defined as the time in days from subject randomization to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first.

Secondary Outcome Measures
NameTimeMethod
Time to Deterioration in Disease SymptomsUp to approximately 51 months from first randomization

Time to deterioration in disease symptoms is measured by the disease symptom domain of the European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Module 20 (EORTC QLQ-MY20).

Time to Deterioration in Physical FunctioningUp to approximately 51 months from first randomization

Time to deterioration in physical functioning is measured by the physical functioning domain of European Organization for Research and Treatment of Cancer Quality of Life Core 30 Question Questionnaire (EORTC-QLQ-C30).

Change from Baseline in PROMIS Fatigue ScoreUp to approximately 51 months from first randomization

Change from baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a score.

Change from Baseline in BPI-SF Worst Pain ScoreUp to approximately 51 months from first randomization

Change from baseline in the Brief Pain Inventory - Short Form (BPI-SF) worst pain score.

Change from Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L)Up to approximately 51 months from first randomization

EQ-5D-5L consists of 2 components: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the participant's self-rated health on a vertical VAS where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine."

Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)Up to approximately 51 months from first randomization

EORTC QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).

Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Module 20 (EORTC QLQ-MY20)Up to approximately 51 months from first randomization

EORTC QLQ-MY20 includes scales for disease symptoms, side effects of treatment, future perspective, and body image. Values for each scale range from 0 to 100.

Duration of response (DOR)Up to approximately 43 months from first randomization

DOR for a participant is defined as the number of days from the date of first documented response (PR or better) to the date of first documented PD or death due to multiple myeloma, whichever occurs first.

Overall Response Rate (ORR)Up to approximately 43 months from first randomization

ORR is defined as the percentage of participants with documented best response (sCR, CR, VGPR or partial response \[PR\]) prior to first documented PD.

Very Good Partial Response or Better Response Rate (VGPR)Up to approximately 43 months from first randomization

VGPR or better response rate is defined as the proportion of participants with documented stringent complete response (sCR), complete response (CR), or VGPR.

Overall survival (OS)Up to approximately 51 months from first randomization

OS is defined as the number of days from the date that the participant was randomized to the date of the participant's death.

Minimal Residual Disease (MRD) Negativity RateUp to approximately 43 months from first randomization

MRD defined as the percentage of participants with MRD negativity status. MRD negativity will be defined at 10\^-5 threshold as measured by centralized testing of bone marrow aspirate samples by next generation sequencing (NGS).

Time to Disease Progression (TTP)Up to approximately 43 months from first randomization

TTP for a participant is defined as the number of days from the date of randomization to the date of first documented PD or death due to multiple myeloma, whichever occurs first.

Time to Response (TTR)Up to approximately 43 months from first randomization

TTR for a participant is defined as the number of days from the date of randomization to the date of first documented response (PR or better).

Cmax of VenetoclaxUp to approximately 225 days from initial dose

Maximum plasma concentration (Cmax) of venetoclax

Trough Concentration (Ctrough) of VenetoclaxUp to approximately 225 days from initial dose

Observed plasma concentration at trough (Ctrough) of venetoclax.

Number of Participants With Adverse Events (AEs)Up to approximately 51 months from first randomization

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Trial Locations

Locations (180)

Duplicate_Herlev Hospital /ID# 223221

🇩🇰

Herlev, Hovedstaden, Denmark

Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407

🇺🇸

Tucson, Arizona, United States

VA Central California Health Care System /ID# 200047

🇺🇸

Fresno, California, United States

University of California, Los Angeles /ID# 171524

🇺🇸

Los Angeles, California, United States

Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904

🇺🇸

Aurora, Colorado, United States

Mayo Clinic /ID# 200075

🇺🇸

Jacksonville, Florida, United States

Cleveland Clinic Florida /ID# 208884

🇺🇸

Weston, Florida, United States

Duplicate_Norton Cancer Institute /ID# 200834

🇺🇸

Louisville, Kentucky, United States

University of Maryland, Baltimore /ID# 217422

🇺🇸

Baltimore, Maryland, United States

Boston Medical Center /ID# 223606

🇺🇸

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer In /ID# 201377

🇺🇸

Detroit, Michigan, United States

Duplicate_Henry Ford Hospital /ID# 171531

🇺🇸

Detroit, Michigan, United States

Mayo Clinic - Rochester /ID# 201091

🇺🇸

Rochester, Minnesota, United States

Columbia University Medical Center /ID# 200715

🇺🇸

New York, New York, United States

Fairview Hospital - Moll Pavilion /ID# 208919

🇺🇸

Cleveland, Ohio, United States

Cleveland Clinic Main Campus /ID# 202247

🇺🇸

Cleveland, Ohio, United States

UPMC Hillman Cancer Ctr /ID# 200063

🇺🇸

Pittsburgh, Pennsylvania, United States

MD Anderson Cancer Center at Texas Medical Center /ID# 200060

🇺🇸

Houston, Texas, United States

Huntsman Cancer Institute /ID# 218406

🇺🇸

Salt Lake City, Utah, United States

VA Puget Sound Health Care System /ID# 222708

🇺🇸

Seattle, Washington, United States

Liverpool Hospital /ID# 202431

🇦🇺

Liverpool, New South Wales, Australia

Sydney Adventist Hospital /ID# 222874

🇦🇺

Wahroonga, New South Wales, Australia

Wollongong Hospital /ID# 205545

🇦🇺

Wollongong, New South Wales, Australia

ICON Cancer Care - Townsville /ID# 206565

🇦🇺

Hyde Park, Queensland, Australia

Icon Cancer Centre /ID# 205663

🇦🇺

South Brisbane, Queensland, Australia

The Queen Elizabeth Hospital /ID# 202432

🇦🇺

Woodville South, South Australia, Australia

Perth Blood Institute Ltd /ID# 206649

🇦🇺

Nedlands, Western Australia, Australia

Arthur J. E. Child Comprehensive Cancer Centre /ID# 218846

🇨🇦

Calgary, Alberta, Canada

BC Cancer - Vancouver /ID# 222804

🇨🇦

Vancouver, British Columbia, Canada

QE II Health Sciences Centre /ID# 218883

🇨🇦

Halifax, Nova Scotia, Canada

CISSS-CA (Centre Integre de sante et de services sociaux de Chaudiere-Appalache) /ID# 218887

🇨🇦

Levis, Quebec, Canada

Beijing Chaoyang Hospital,Capital Medical University /ID# 216014

🇨🇳

Beijing, Beijing, China

Peking University Third Hospital /ID# 216371

🇨🇳

Beijing, Beijing, China

Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 216040

🇨🇳

Beijing, Beijing, China

Sun Yat-Sen University Cancer Center /ID# 223828

🇨🇳

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital /ID# 215860

🇨🇳

Guangzhou, Guangdong, China

Henan Cancer Hospital /ID# 215987

🇨🇳

Zhengzhou, Henan, China

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 215850

🇨🇳

Wuhan, Hubei, China

Nanjing Drum Tower Hospital /ID# 223143

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University /ID# 216094

🇨🇳

Suzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University /ID# 216954

🇨🇳

Nanchang, Jiangxi, China

The First Hospital of China Medical University /ID# 215996

🇨🇳

Shenyang, Liaoning, China

Shengjing Hospital of China Medical University /ID# 223435

🇨🇳

Shenyang, Liaoning, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 216643

🇨🇳

Shanghai, Shanghai, China

Shanghai Tongji Hospital /ID# 218865

🇨🇳

Shanghai, Shanghai, China

West China Hospital, Sichuan University /ID# 216647

🇨🇳

Chengdu, Sichuan, China

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 216041

🇨🇳

Tianjin, Tianjin, China

Tianjin Medical University Cancer Institute & Hospital /ID# 223550

🇨🇳

Tianjin, Tianjin, China

Aalborg University Hospital /ID# 223220

🇩🇰

Aalborg, Nordjylland, Denmark

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215989

🇨🇳

Hangzhou, Zhejiang, China

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 218691

🇨🇳

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University /ID# 218953

🇨🇳

Wenzhou, Zhejiang, China

Beijing Chaoyang Hospital, Capital Medical University(West campus) /ID# 234033

🇨🇳

Beijing, China

Fakultní Nemocnice Brno - Jihlavská /ID# 204512

🇨🇿

Brno, Brno-mesto, Czechia

Fakultní nemocnice Hradec Králové - Sokolská /ID# 221291

🇨🇿

Hradec Králové, Hradec Kralove, Czechia

Fakultni Nemocnice Ostrava /ID# 204515

🇨🇿

Ostrava, Ostrava-mesto, Czechia

Fakultni nemocnice Olomouc /ID# 221290

🇨🇿

Olomouc, Czechia

Vseobecna fakultni nemocnice v Praze /ID# 221166

🇨🇿

Praha, Czechia

Odense University Hospital /ID# 223217

🇩🇰

Odense, Syddanmark, Denmark

Sygehus Lillebalt, Vejle /ID# 223216

🇩🇰

Vejle, Syddanmark, Denmark

Duplicate_Roskilde Hospital /ID# 223366

🇩🇰

Roskilde, Denmark

Hopital Pitie Salpetriere /ID# 214173

🇫🇷

Paris Cedex 13, Ile-de-France, France

Duplicate_CHU Grenoble - Hopital Michallon /ID# 223182

🇫🇷

La Tronche, Isere, France

CHU Reims - Hôpital Robert Debre /ID# 233907

🇫🇷

Reims CEDEX, Marne, France

CHRU Nancy - Hopitaux de Brabois /ID# 201076

🇫🇷

Vandoeuvre-les-Nancy, Meurthe-et-Moselle, France

CHRU Lille - Hopital Claude Huriez /ID# 202213

🇫🇷

Lille, Nord, France

Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 202211

🇫🇷

Creteil, Paris, France

CHU de Nantes, Hotel Dieu -HME /ID# 200099

🇫🇷

Nantes, Pays-de-la-Loire, France

HCL - Hopital Lyon Sud /ID# 200097

🇫🇷

Pierre Benite CEDEX, Rhone, France

Centre Henri Becquerel /ID# 223186

🇫🇷

Rouen, Seine-Maritime, France

CH Henri Duffaut /ID# 234154

🇫🇷

Avignon CEDEX 9, Vaucluse, France

Robert-Bosch-Krankenhaus /ID# 223947

🇩🇪

Stuttgart, Baden-Wuerttemberg, Germany

Universitaetsklinikum Tuebingen /ID# 238646

🇩🇪

Tubingen, Baden-Wuerttemberg, Germany

Universitaetsklinikum Wuerzburg /ID# 200055

🇩🇪

Wuerzburg, Bayern, Germany

Klinikum Chemnitz gGmbH /ID# 233797

🇩🇪

Chemnitz, Sachsen, Germany

Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 201830

🇩🇪

Kiel, Schleswig-Holstein, Germany

Universitaetsklinikum Jena /ID# 201254

🇩🇪

Jena, Thueringen, Germany

Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 200051

🇩🇪

Berlin, Germany

Universitaetsklinikum Hamburg-Eppendorf /ID# 215495

🇩🇪

Hamburg, Germany

Asklepios Klinik Altona /ID# 222506

🇩🇪

Hamburg, Germany

Alexandra General Hospital /ID# 202386

🇬🇷

Athens, Attiki, Greece

University General Hospital of Heraklion PA.G.N.I /ID# 222879

🇬🇷

Heraklion, Kriti, Greece

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213982

🇬🇷

Athens, Greece

University Gen Hosp of Patra /ID# 201691

🇬🇷

Patras, Greece

Theageneio Anticancer Hospital /ID# 213983

🇬🇷

Thessaloniki, Greece

General Hospital of Thessaloniki George Papanikolaou /ID# 201692

🇬🇷

Thessaloniki, Greece

Rambam Health Care Campus /ID# 169678

🇮🇱

Haifa, H_efa, Israel

Bnai Zion Medical Center /ID# 169466

🇮🇱

Haifa, H_efa, Israel

The Lady Davis Carmel Medical Center /ID# 222969

🇮🇱

Haifa, H_efa, Israel

Duplicate_Assuta Ashdod Medical Center /ID# 222968

🇮🇱

Ashdod, HaDarom, Israel

Soroka University Medical Center /ID# 218768

🇮🇱

Be'er Sheva, HaDarom, Israel

The Chaim Sheba Medical Center /ID# 169778

🇮🇱

Ramat Gan, Tel-Aviv, Israel

Tel Aviv Sourasky Medical Center /ID# 169437

🇮🇱

Tel Aviv, Tel-Aviv, Israel

Hadassah /ID# 169474

🇮🇱

Jerusalem, Yerushalayim, Israel

Rabin Medical Center /ID# 244611

🇮🇱

Petah Tikva, Israel

Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 170952

🇮🇹

Bologna, Emilia-Romagna, Italy

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 170962

🇮🇹

Torino, Piemonte, Italy

Irccs-Crob /Id# 170955

🇮🇹

Rionero In Vulture, Potenza, Italy

Azienda Ospedaliero Universitaria delle Marche /ID# 170950

🇮🇹

Ancona, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 212498

🇮🇹

Milano, Italy

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 222988

🇮🇹

Palermo, Italy

Azienda Ospedaliera Santa Maria Terni /ID# 170948

🇮🇹

Terni, Italy

Nagoya City University Hospital /ID# 170880

🇯🇵

Nagoya shi, Aichi, Japan

The Jikei University Kashiwa Hospital /ID# 223031

🇯🇵

Kashiwa-shi, Chiba, Japan

Kyushu University Hospital /ID# 171117

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Ogaki Municipal Hospital /ID# 171043

🇯🇵

Ogaki-shi, Gifu, Japan

Gunma University Hospital /ID# 170966

🇯🇵

Maebashi-shi, Gunma, Japan

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 171255

🇯🇵

Hiroshima-shi, Hiroshima, Japan

Kobe City Medical Center General Hospital /ID# 170992

🇯🇵

Kobe-shi, Hyogo, Japan

Duplicate_National Hospital Organization Mito Medical Center /ID# 171187

🇯🇵

Higashi Ibaraki-gun, Ibaraki, Japan

Hitachi General Hospital /ID# 200843

🇯🇵

Hitachi-shi, Ibaraki, Japan

Iwate Medical University Hospital /ID# 222849

🇯🇵

Shiwa-gun, Iwate, Japan

Tohoku University Hospital /ID# 201935

🇯🇵

Sendai-shi, Miyagi, Japan

Okayama Medical Center /ID# 200119

🇯🇵

Okayama-shi, Okayama, Japan

Japanese Red Cross Osaka Hospital /ID# 171493

🇯🇵

Osaka-shi, Osaka, Japan

The University of Osaka Hospital /ID# 201966

🇯🇵

Suita-shi, Osaka, Japan

Tokushima University Hospital /ID# 202571

🇯🇵

Tokushima-shi, Tokushima, Japan

The Jikei University Hospital /ID# 239014

🇯🇵

Minato-ku, Tokyo, Japan

Japanese Red Cross Medical Center /ID# 171256

🇯🇵

Shibuya-ku, Tokyo, Japan

Yamagata University Hospital /ID# 238329

🇯🇵

Yamagata-shi, Yamagata, Japan

Duplicate_Gachon University Gil Medical Center /ID# 202827

🇰🇷

Incheon, Gyeonggido, Korea, Republic of

Seoul National University Hospital /ID# 202711

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Samsung Medical Center /ID# 202710

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 234045

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Ulsan University Hospital /ID# 222716

🇰🇷

Ulsan, Ulsan Gwang Yeogsi, Korea, Republic of

Yonsei University Health System Severance Hospital /ID# 202709

🇰🇷

Seoul, Korea, Republic of

Moscow State budget healthcare /ID# 169685

🇷🇺

Moscow, Moskva, Russian Federation

Research Institute of Fundamental and Clinical Immunology /ID# 223594

🇷🇺

Novosibirsk, Novosibirskaya Oblast, Russian Federation

LLC Novaya Klinika /ID# 169689

🇷🇺

Pyatigorsk, Stavropol Skiy Kray, Russian Federation

City Clinical Hospital #52 /ID# 206289

🇷🇺

Moscow, Russian Federation

Leningrad Regional Clinical Hospital /ID# 202776

🇷🇺

Saint Petersburg, Russian Federation

Almazov National Medical Research Centre /ID# 169681

🇷🇺

Sankt-Peterburg, Russian Federation

Tula Regional Clinical Hospital /ID# 223226

🇷🇺

Tula, Russian Federation

National University Hospital /ID# 203988

🇸🇬

Singapore, Singapore

Singapore General Hospital /ID# 202131

🇸🇬

Singapore, Singapore

Tan Tock Seng Hospital /ID# 204374

🇸🇬

Singapore, Singapore

Hospital Universitari Son Espases /ID# 222889

🇪🇸

Palma de Mallorca, Illes Balears, Spain

Hospital Costa del Sol /ID# 234083

🇪🇸

Marbella, Malaga, Spain

Complejo Hospitalario Universitario Ourense /ID# 222876

🇪🇸

Orense, Ourense, Spain

Hospital Universitario Canarias /ID# 238452

🇪🇸

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain

Hospital Universitario Vall d'Hebron /ID# 218106

🇪🇸

Barcelona, Spain

Instituto Catalan de Oncologia (ICO) Girona /ID# 171311

🇪🇸

Girona, Spain

Hospital de Leon /ID# 233878

🇪🇸

Leon, Spain

Hospital Universitario Fundacion Jimenez Diaz /ID# 171304

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre /ID# 171288

🇪🇸

Madrid, Spain

Hospital Universitario La Paz /ID# 218107

🇪🇸

Madrid, Spain

Hospital Universitario de Salamanca /ID# 171294

🇪🇸

Salamanca, Spain

Hospital Universitario Virgen del Rocio /ID# 171286

🇪🇸

Sevilla, Spain

Hospital General Universitario de Toledo /ID# 222887

🇪🇸

Toledo, Spain

Hospital Universitario y Politecnico La Fe /ID# 234019

🇪🇸

Valencia, Spain

Sunderby sjukhus /ID# 201314

🇸🇪

Lulea, Norrbottens Lan, Sweden

Sodra Alvsborgs sjukhus /ID# 213061

🇸🇪

Boras, Vastra Gotalands Lan, Sweden

Duplicate_Universitetssjukhuset Linköping /ID# 200789

🇸🇪

Linkoping, Vastra Gotalands Lan, Sweden

Uddevalla sjukhus /ID# 201315

🇸🇪

Uddevalla, Vastra Gotalands Lan, Sweden

Cukurova Universitesi Tip Fakultesi /ID# 201955

🇹🇷

Saricam Adana, Adana, Turkey

Izmir Ekonomi Universitesi Ozel Medicalpoint Hastanesi /ID# 201954

🇹🇷

Karsiyaka, Izmir, Turkey

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 201956

🇹🇷

Ankara, Turkey

Gazi University Medical Faculty /ID# 222698

🇹🇷

Ankara, Turkey

Ankara Univ Medical Faculty /ID# 201881

🇹🇷

Ankara, Turkey

Istanbul University Istanbul Medical Faculty /ID# 201953

🇹🇷

Istanbul, Turkey

Bagcilar Medipol Mega Universite Hastanesi /ID# 222914

🇹🇷

Istanbul, Turkey

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 201952

🇹🇷

Istanbul, Turkey

Ege University Medical Faculty /ID# 222697

🇹🇷

Izmir, Turkey

Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary /ID# 223943

🇺🇦

Cherkasy, Cherkaska Oblast, Ukraine

Communal non-profit enterprise Regional Center of Oncology /ID# 223945

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

MNI Khmelnytskyi Regional Hospital of Khmelnytskyi Regional Council /ID# 223942

🇺🇦

Khmelnytskyi, Ukraine

National Cancer Institute /ID# 223944

🇺🇦

Kyiv, Ukraine

SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 223941

🇺🇦

Lviv, Ukraine

Addenbrooke's Hospital /ID# 223097

🇬🇧

Cambridge, Cambridgeshire, United Kingdom

Hammersmith Hospital /ID# 171446

🇬🇧

London, England, United Kingdom

University College London Hospital /ID# 171428

🇬🇧

London, Greater London, United Kingdom

Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 218213

🇬🇧

Norwich, Norfolk, United Kingdom

Duplicate_Nottingham University Hospitals NHS Trust /ID# 223292

🇬🇧

Nottingham, Nottinghamshire, United Kingdom

Duplicate_NHS Greater Glasgow and Clyde /ID# 202199

🇬🇧

Glasgow, Scotland, United Kingdom

Duplicate_University Hospitals North Midlands - Royal Stoke University Hospital /ID# 218355

🇬🇧

Stoke-on-Trent, Staffordshire, United Kingdom

Duplicate_Duplicate_Lewisham and Greenwich NHS Trust /ID# 171445

🇬🇧

London, United Kingdom

Manchester University NHS Foundation Trust /ID# 171440

🇬🇧

Manchester, United Kingdom

Portsmouth Hospitals University NHS Trust /ID# 171444

🇬🇧

Portsmouth, United Kingdom

Royal Berkshire NHS Foundation Trust /ID# 217835

🇬🇧

Reading, United Kingdom

Duplicate_Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire /ID# 171447

🇬🇧

Sheffield, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath